-
Mashup Score: 14In Memoriam: C. Norman Coleman, M.D., (1945–2024) - 12 day(s) ago
Mentorship, Partnership, Science, and Kindness Always
Source: www.thegreenjournal.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 47
In 2023, the Common Sense Oncology (CSO) movement was launched with the goal of recalibrating cancer care to focus on outcomes that matter to patients. We extend the three CSO pillars – evidence generation, interpretation and communication – to radiation oncology and advocate for better evidence demonstrating the value of our modality.
Source: www.thegreenjournal.comCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 47
In 2023, the Common Sense Oncology (CSO) movement was launched with the goal of recalibrating cancer care to focus on outcomes that matter to patients. We extend the three CSO pillars – evidence generation, interpretation and communication – to radiation oncology and advocate for better evidence demonstrating the value of our modality.
Source: www.thegreenjournal.comCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 14A joint physics and radiobiology DREAM team vision – Towards better response prediction models to advance radiotherapy - 19 day(s) ago
RT is one of the cornerstones of cancer treatment. However, it comes with inevitable radiation dose to normal tissues. Achieving best possible treatment outcome for individual patients through informed selection of modalities and their careful application requires a quantitative description of their contribution to tumour control and side-effects with the help of models (see Table 1).
Source: www.thegreenjournal.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 44
In 2023, the Common Sense Oncology (CSO) movement was launched with the goal of recalibrating cancer care to focus on outcomes that matter to patients. We extend the three CSO pillars – evidence generation, interpretation and communication – to radiation oncology and advocate for better evidence demonstrating the value of our modality.
Source: www.thegreenjournal.comCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 67
Lung cancer is the leading cause of cancer related mortality in the United States [1]. Brain metastases are common in lung cancer with 10 % of patients with advanced non-small cell lung cancer (NSCLC) presenting with synchronous brain metastases and 40 % developing brain metastases at some point in the course of the disease [2]. Historically, patients with brain metastases from NSCLC were treated with whole brain radiation therapy (WBRT), however, more recent retrospective and prospective studies have shown that limited numbers of brain metastases can be treated with stereotactic radiosurgery (SRS) without compromising survival [3,4].
Source: www.thegreenjournal.comCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 25Diagnosis and management of pneumonitis following chemoradiotherapy and immunotherapy in stage III non-small cell lung cancer - 3 month(s) ago
Non-small cell lung carcinoma (NSCLC) stage III accounts for 25–30 % of all patients with NSCLC [1]. Patients with stage III NSCLC have frequently unresectable disease [2]. Concurrent chemoradiotherapy (cCRT) is the preferred non-surgical treatment for such patients, yet the best 5-year overall survival (OS) (32 %) and progression free survival (PFS) (18 %) reported in a phase III randomized controlled trial are disappointing [3]. The PACIFIC regimen is the paradigm establishing a survival benefit for adjuvant durvalumab, an anti—PD-L1 antibody after cCRT [4].
Source: www.thegreenjournal.comCategories: General Medicine News, Hem/OncsTweet-
A critical report from Amsterdam demonstrates how often drug-related pneumonitis can be misdiagnosed in patients receiving thoracic radiation therapy. When it occurs, it can lead to premature termination of life-prolonging checkpoint inhibitors. 🇳🇱 #radonc https://t.co/pqJ8ACGiTB https://t.co/PvbfKXkaOn
-
-
Mashup Score: 16
Head and neck squamous cell carcinoma (HNSCC) is the 6th leading cancer worldwide1. Although diagnostics as well as treatment technologies are advancing, patients are still responding heterogeneously to the treatment, which is at least partly due to their different tumour biology. Within the last decade, the infection with the human papillomavirus has been identified to be a driver for the development of HNSCC, especially of oropharyngeal squamous cell carcinoma (OPSCC)2,3. In addition to its impact on the etiology, HPV-driven HNSCC are also more radiosensitive3 and less likely to develop metastatic disease, suggesting that patients with these tumours may benefit from less intense treatment with a similar oncological outcome but improved quality of life.
Source: www.thegreenjournal.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 2Prostate volume variation during 1.5T MR-guided adaptive stereotactic body radiotherapy (SBRT) and correlation with treatment toxicity - 5 month(s) ago
In the last years, Stereotactic body radiotherapy (SBRT) has demonstrated to be an effective and safe treatment option for localized prostate cancer (PCa) in low and intermediate-risk patients, by producing comparable results to conventional and softly-hypofractionated schedules [1–3]. Prostate SBRT requires high precision in patients’ positioning to ensure an accurate dose delivery. Prostate SBRT is generally characterized by a low rate of side effects, and few predictive factors are available to identify the early onset of symptoms [4].
Source: www.thegreenjournal.comCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 1Value-based radiotherapy: A new chapter of the ESTRO-HERO project - 6 month(s) ago
Radiotherapy is one of the cornerstones of multidisciplinary cancer care, required by at least one out of two cancer patients, and improving local control, survival and quality-of-life [1–3]. Due to the increasing cancer incidence, the numbers of patients that will need radiotherapy are expected to further rise dramatically in the years to come [1,4]. Unfortunately, radiotherapy access remains far from optimal, especially in low-and middle-income countries, mainly due to the lack in human and capital resources [1,5].
Source: www.thegreenjournal.comCategories: General Medicine News, Hem/OncsTweet
In Memoriam: C. Norman Coleman, M.D. (1945–2024) Touching and inspiring homage in @RadiotherapyOn1 🙏 @_MichaelBaumann @PBlanchardMD @theNCI @NCICTEP_ClinRes ➡️https://t.co/jXFecQ7JBm